CN1774500B - 用于瞬时或稳定表达外源分子的表达盒和载体 - Google Patents

用于瞬时或稳定表达外源分子的表达盒和载体 Download PDF

Info

Publication number
CN1774500B
CN1774500B CN2004800101473A CN200480010147A CN1774500B CN 1774500 B CN1774500 B CN 1774500B CN 2004800101473 A CN2004800101473 A CN 2004800101473A CN 200480010147 A CN200480010147 A CN 200480010147A CN 1774500 B CN1774500 B CN 1774500B
Authority
CN
China
Prior art keywords
expression cassette
sequence
seq
polynucleotide
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2004800101473A
Other languages
English (en)
Chinese (zh)
Other versions
CN1774500A (zh
Inventor
威廉·P·西斯克
霍利·普伦蒂斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec MA Inc filed Critical Biogen Idec MA Inc
Publication of CN1774500A publication Critical patent/CN1774500A/zh
Application granted granted Critical
Publication of CN1774500B publication Critical patent/CN1774500B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Tents Or Canopies (AREA)
  • Paints Or Removers (AREA)
CN2004800101473A 2003-02-14 2004-02-13 用于瞬时或稳定表达外源分子的表达盒和载体 Expired - Lifetime CN1774500B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44817903P 2003-02-14 2003-02-14
US60/448,179 2003-02-14
PCT/US2004/004407 WO2004074439A2 (en) 2003-02-14 2004-02-13 An expression cassette and vector for transient or stable expression of exogenous molecules

Publications (2)

Publication Number Publication Date
CN1774500A CN1774500A (zh) 2006-05-17
CN1774500B true CN1774500B (zh) 2011-03-02

Family

ID=32908549

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800101473A Expired - Lifetime CN1774500B (zh) 2003-02-14 2004-02-13 用于瞬时或稳定表达外源分子的表达盒和载体

Country Status (21)

Country Link
US (2) US7494805B2 (https=)
EP (1) EP1594955B1 (https=)
JP (2) JP2006517802A (https=)
KR (1) KR20050101554A (https=)
CN (1) CN1774500B (https=)
AT (1) ATE553185T1 (https=)
AU (1) AU2004213797B2 (https=)
BR (1) BRPI0407487A (https=)
CA (1) CA2515481A1 (https=)
DK (1) DK1594955T3 (https=)
EA (2) EA008439B1 (https=)
ES (1) ES2384973T3 (https=)
IL (1) IL170178A (https=)
IS (1) IS7974A (https=)
MX (1) MXPA05008523A (https=)
NO (1) NO20054202L (https=)
NZ (1) NZ542316A (https=)
PL (1) PL378110A1 (https=)
RS (1) RS20050614A (https=)
WO (1) WO2004074439A2 (https=)
ZA (1) ZA200506413B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1594955T3 (da) * 2003-02-14 2012-06-25 Biogen Idec Inc Ekspressionskassette og vektor til transient eller stabil ekspression af eksogene molekyler
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
WO2005038020A1 (en) * 2003-10-14 2005-04-28 Biogen Idec Ma Inc. Flp-mediated recombination
CA2559280A1 (en) * 2004-03-15 2005-09-29 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
WO2008073184A2 (en) * 2006-10-18 2008-06-19 The Scripps Research Institute Genetic incorporation of unnatural amino acids into proteins in mammalian cells
WO2011017319A1 (en) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US8809617B2 (en) * 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
PH12012501163A1 (en) * 2009-12-21 2019-07-10 Sanofi Aventis Transgenic non-human animal and uses thereof
UY33126A (es) * 2009-12-21 2011-07-29 Sanofi Sa Animal transgénico no humano y sus usos
US8993316B2 (en) 2011-11-16 2015-03-31 Brian P. Hanley Methods and compositions for gene therapy and GHRH therapy
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
CN104812901B (zh) 2012-09-13 2018-08-10 美国印第安纳大学研究和技术公司 赋予植物抗病性的组合物和系统及其使用方法
AU2013359419B2 (en) 2012-12-10 2018-03-15 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
AU2014246731A1 (en) * 2013-03-30 2015-11-19 Usha Biotech Limited Methods and constructs for expressing biologically active proteins in mammalian cells
JP6581969B2 (ja) * 2014-04-24 2019-09-25 アキュルナ株式会社 タンパク質発現を向上させる方法およびタンパク質発現用組成物
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
US11415263B2 (en) * 2020-03-20 2022-08-16 Edwards Vacuum Llc Conversion kit for a support frame, a support frame and an integrated vacuum system mounted in a support frame

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194176B1 (en) * 1996-01-19 2001-02-27 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
WO2001029208A1 (en) * 1999-10-16 2001-04-26 Artemis Pharmaceuticals Gmbh Conditional gene trapping construct for the disruption of genes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717430D0 (en) * 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
ES2198025T3 (es) 1991-10-25 2004-01-16 Immunex Corporation Anticuerpos contra cd40-l.
AU678154B2 (en) 1992-04-02 1997-05-22 Sembiosys Genetics Inc. Oil-body protein cis-elements as regulatory signals
AU698739B2 (en) 1995-06-06 1998-11-05 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
IL122174A (en) 1995-06-07 2004-07-25 Immunex Corp Dna encoding a cd40l mutein and a cd40l polypeptide encoded by said dna
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
EP0914441A2 (en) * 1996-04-23 1999-05-12 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
AU8589998A (en) 1997-07-24 1999-02-16 Valentis, Inc. Ghrh expression system and methods of use
AU2324999A (en) * 1998-01-16 1999-08-02 California Pacific Medical Center Research Institute Methods and compositions for gene delivery
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
WO1999061066A2 (en) * 1998-05-27 1999-12-02 Avigen, Inc. Convection-enhanced delivery of aav vectors
EP1292686A1 (en) 2000-06-07 2003-03-19 Smittskyddsinstitutet Gene expression cassette and its use
JP2004502426A (ja) 2000-07-05 2004-01-29 トランジェーヌ、ソシエテ、アノニム 平滑筋の発現を制御するキメラプロモーター
JP2002233374A (ja) * 2001-02-06 2002-08-20 Japan Science & Technology Corp 遺伝子導入及び／又は遺伝子欠損非ヒト動物作製用ベクター
DE10133407A1 (de) 2001-07-13 2003-01-23 Basf Ag Expressionskassetten zur transgenen Expression von Nukleinsäuren
US20030235823A1 (en) * 2002-06-24 2003-12-25 The University Of Alabama Nucleotide sequences that code for torsin genes, torsin proteins, and methods of using the same to treat protein-aggregation
DK1594955T3 (da) 2003-02-14 2012-06-25 Biogen Idec Inc Ekspressionskassette og vektor til transient eller stabil ekspression af eksogene molekyler

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194176B1 (en) * 1996-01-19 2001-02-27 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
WO2001029208A1 (en) * 1999-10-16 2001-04-26 Artemis Pharmaceuticals Gmbh Conditional gene trapping construct for the disruption of genes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C.B. BREWER.Cytomegalovirus Plasmid Vectors for Permanent Lines ofPolarised Epithelial cell.METHODS IN CELL BIOLOGY 43.1994,(43),233-245.
C.B. BREWER.Cytomegalovirus Plasmid Vectors for Permanent Lines ofPolarised Epithelial cell.METHODS IN CELL BIOLOGY 43.1994,(43),233-245. *
D. R. THOMSEN.PROMOTER REGULATORY REGION OF THE MAJORIMMEDIATE EARLY GENE OF HUMANCYTOMEGALOVIRUS.PROC. NATL. ACAD. SCI 81.1984,(81),659-663.
D. R. THOMSEN.PROMOTER REGULATORY REGION OF THE MAJORIMMEDIATE EARLY GENE OF HUMANCYTOMEGALOVIRUS.PROC. NATL. ACAD. SCI 81.1984,(81),659-663. *

Also Published As

Publication number Publication date
NO20054202D0 (no) 2005-09-09
IL170178A (en) 2011-12-29
EP1594955A4 (en) 2006-07-19
JP2006517802A (ja) 2006-08-03
PL378110A1 (pl) 2006-03-06
KR20050101554A (ko) 2005-10-24
ATE553185T1 (de) 2012-04-15
BRPI0407487A (pt) 2006-02-14
MXPA05008523A (es) 2005-10-20
ZA200506413B (en) 2006-04-26
NZ542316A (en) 2006-04-28
EP1594955B1 (en) 2012-04-11
AU2004213797B2 (en) 2009-09-17
WO2004074439A9 (en) 2004-12-23
IS7974A (is) 2005-08-11
DK1594955T3 (da) 2012-06-25
US20060141625A1 (en) 2006-06-29
RS20050614A (sr) 2007-12-31
WO2004074439A2 (en) 2004-09-02
EA200501296A1 (ru) 2006-04-28
WO2004074439A3 (en) 2004-10-28
EA200700469A1 (ru) 2008-10-30
US20100158879A1 (en) 2010-06-24
US7494805B2 (en) 2009-02-24
CA2515481A1 (en) 2004-09-02
EA008439B1 (ru) 2007-06-29
JP2010213718A (ja) 2010-09-30
EP1594955A2 (en) 2005-11-16
HK1084690A1 (en) 2006-08-04
NO20054202L (no) 2005-11-11
AU2004213797A1 (en) 2004-09-02
CN1774500A (zh) 2006-05-17
ES2384973T3 (es) 2012-07-16

Similar Documents

Publication Publication Date Title
CN1774500B (zh) 用于瞬时或稳定表达外源分子的表达盒和载体
AU2015263150B2 (en) Lentiviral vectors
US9163219B2 (en) Single expression vector for generation of a virus with a segmented genome
DE60018171T2 (de) Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen.
CN112552380B (zh) 一种SARS-CoV-2病毒的免疫原及其应用
CN106520830A (zh) 利用CRISPR/Cas9对线粒体基因组进行靶向编辑的方法
JP2006517802A5 (https=)
CN110904155B (zh) 一种碱基编辑器及其制备方法和应用
CN107312790A (zh) 一种可编程的多位点特异性的转录抑制系统及其应用
AU2024217163A1 (en) Transposase, transposon, transposon system, and use thereof
CN120210288B (zh) 一种D/Yama2019遗传进化谱系丁型流感病毒反向遗传操作系统
CN113583978A (zh) 3种重组腺病毒以及SARS-CoV-2 Spike蛋白的RBD以及它们的应用
AU2006297112B2 (en) Regulatable fusion promoters
CN117858713A (zh) 工程改造基于b细胞的蛋白质工厂以治疗严重疾病
CN107090473A (zh) 抗菌肽pr39和pg1共表达载体和转pr39和pg1基因小鼠制备方法
CN118895283B (zh) 一种伪狂犬病毒Bartha K61疫苗株基因组分段克隆和拯救的反向遗传操作系统及其构建方法与应用
US20240082327A1 (en) Retroviral vectors
HK40107754A (zh) 工程改造基於b细胞的蛋白质工厂以治疗严重疾病
CN109929864A (zh) 核苷酸序列tWPRE及其基因表达载体和应用
NO845186L (no) Vektorsystem for innfoering av heterolog dna i eykaryotiske celler.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: BIOGEN MA INC.

Free format text: FORMER NAME: BIOGEN IDEC MA

CP01 Change in the name or title of a patent holder

Address after: Massachusetts, USA

Patentee after: BIOGEN MA Inc.

Address before: Massachusetts, USA

Patentee before: Biogen Idec MA Inc.

CX01 Expiry of patent term

Granted publication date: 20110302

CX01 Expiry of patent term